Indian PM Visit an Opportunity to Resolve Trade Disagreements, Says Think Tank Paper
The summit planned for September between President Barack Obama and Indian Prime Minister Narendra Modi represents an important opportunity for both countries to bridge differences on trade rules and policy, said President of The National Bureau of Asian Research Richard…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
Ellings in a recent paper. The two sides have been pitted against each other in conflicts over localization barriers and alleged Indian intellectual property (IP) right violations. “The IP challenge from India, while not as significant in scope or scale as that from China, has its own worrisome components,” said Ellings. “The unpredictable use of compulsory licenses is particularly nettlesome for affected U.S. sectors, especially pharmaceuticals, where two-thirds of patented drugs are on a list of potential compulsory licenses.” Many U.S. industry and administration officials have lambasted India for failing to stop a pervasive pharmaceutical counterfeit industry in the country, but the Office of the U.S. Trade Representative (USTR) did not place India on the “priority watch list” during a recent review (see 14050101).